(Q28305315)

English

Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy

scientific article

In more languages

Statements

scholarly article

0 references

1 reference

Europe PubMed Central

Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy (English)

0 references

1 reference

based on heuristic

inferred from title

atherosclerosis

1 reference

based on heuristic

inferred from title

author name string

Daniel Steinberg

1

0 references

language of work or name

0 references

publication date

July 2006

0 references

Journal of Lipid Research

0 references

47

0 references

7

0 references

1339-51

0 references

Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part I

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Thematic review series: the pathogenesis of atherosclerosis: an interpretive history of the cholesterol controversy, part III: mechanistically defining the role of hyperlipidemia

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part IV: the 1984 coronary primary prevention trial ends it--almost

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Chemistry, biochemistry, and pharmacology of HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Hypolipidemic effects in monkeys of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Appearance of crystalloid endoplasmic reticulum in compactin-resistant Chinese hamster cells with a 500-fold increase in 3-hydroxy-3-methylglutaryl-coenzyme A reductase

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Therapeutic effects of ML-236B in primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Safety of fenofibrate--US and worldwide experience

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

A receptor-mediated pathway for cholesterol homeostasis

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Report of the Conference on Low Blood Cholesterol: Mortality Associations

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Efficacy of simvastatin and ezetimibe in treating hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Inflammation and atherosclerosis

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Atherosclerosis. the road ahead

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Immune mechanisms in atherosclerosis

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

The cholesterol controversy is over. Why did it take so long?

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Toward evidence-based medical statistics. 1: The P value fallacy

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Toward evidence-based medical statistics. 2: The Bayes factor

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Over-the-counter statins and cardiovascular disease prevention: perspectives, challenges, and opportunities

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R600009-JLR200

21 January 2018

Identifiers

10.1194/JLR.R600009-JLR200

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28305315&oldid=1246077455"